Display options
Cite
Fountzilas E, Kotoula V, Koliou GA, et al. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget. 2020;11(1):1-14doi: 10.18632/oncotarget.27338.
Fountzilas, E., Kotoula, V., Koliou, G. A., Giannoulatou, E., Gogas, H., Papadimitriou, C., Tikas, I., Zhang, J., Papadopoulou, K., Zagouri, F., Christodoulou, C., Koutras, A., Makatsoris, T., Chrisafi, S., Linardou, H., Varthalitis, I., Papatsibas, G., Razis, E., Papakostas, P., Samantas, E., Aravantinos, G., Bafaloukos, D., Kosmidis, P., Koumarianou, A., Psyrri, A., Pentheroudakis, G., Pectasides, D., Futreal, A., Fountzilas, G., & Tsimberidou, A. M. (2020). Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget, 11(1), 1-14. https://doi.org/10.18632/oncotarget.27338
Fountzilas, Elena, et al. "Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative." Oncotarget vol. 11,1 (2020): 1-14. doi: https://doi.org/10.18632/oncotarget.27338
Fountzilas E, Kotoula V, Koliou GA, Giannoulatou E, Gogas H, Papadimitriou C, Tikas I, Zhang J, Papadopoulou K, Zagouri F, Christodoulou C, Koutras A, Makatsoris T, Chrisafi S, Linardou H, Varthalitis I, Papatsibas G, Razis E, Papakostas P, Samantas E, Aravantinos G, Bafaloukos D, Kosmidis P, Koumarianou A, Psyrri A, Pentheroudakis G, Pectasides D, Futreal A, Fountzilas G, Tsimberidou AM. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget. 2020 Jan 07;11(1):1-14. doi: 10.18632/oncotarget.27338. eCollection 2020 Jan 07. PMID: 32002119; PMCID: PMC6967777.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2020 Jan 07;11(1):1-14. doi: 10.18632/oncotarget.27338. eCollection 2020 Jan 07.

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.

Oncotarget

Elena Fountzilas, Vassiliki Kotoula, Georgia-Angeliki Koliou, Eleni Giannoulatou, Helen Gogas, Christos Papadimitriou, Ioannis Tikas, Jianhua Zhang, Kyriaki Papadopoulou, Flora Zagouri, Christos Christodoulou, Angelos Koutras, Thomas Makatsoris, Sofia Chrisafi, Helena Linardou, Ioannis Varthalitis, George Papatsibas, Evangelia Razis, Pavlos Papakostas, Epaminontas Samantas, Gerasimos Aravantinos, Dimitrios Bafaloukos, Paris Kosmidis, Anna Koumarianou, Amanda Psyrri, Georgios Pentheroudakis, Dimitrios Pectasides, Andrew Futreal, George Fountzilas, Apostolia M Tsimberidou

Affiliations

  1. The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Houston, TX, USA.
  2. Current address: Hellenic Cooperative Oncology Group, Athens, Greece.
  3. Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
  4. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
  5. Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
  6. Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
  7. The University of New South Wales, Kensington, NSW, Australia.
  8. First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  9. Oncology Unit, Aretaieion Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  10. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  11. Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  12. Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
  13. Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece.
  14. Oncology Unit, Metropolitan Hospital, Piraeus, Greece.
  15. First Department of Medical Oncology, Henry Dunant Hospital, Athens, Greece.
  16. Oncology Department, University General Hospital of Larissa, Larissa, Greece.
  17. Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
  18. Oncology Unit, Hippokration Hospital, Athens, Greece.
  19. Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
  20. Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
  21. First Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
  22. Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
  23. Fourth Department of Internal Medicine, Attikon University Hospital, Athens, Greece.
  24. Section of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  25. Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece.
  26. Society for Study of Clonal Heterogeneity of Neoplasia (EMEKEN), Ioannina, Greece.
  27. Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece.
  28. The University of Texas MD Anderson Cancer Center, Department of Genomic Medicine, Houston, TX, USA.
  29. Aristotle University of Thessaloniki, Thessaloniki, Greece.

PMID: 32002119 PMCID: PMC6967777 DOI: 10.18632/oncotarget.27338

[No abstract available.]

Copyright: Fountzilas et al.

Keywords: actionable gene; next-generation sequencing; pathogenic mutation; precision oncology; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST Fountzilas E: Travel: Merck, K.A.M. oncology/hematology, stock: Deciphera, Kotoula V: No conflict of interest (5/2019), Koliou GA: No conflict of interest (5/2019), Giannoulatou

References

  1. Int J Cancer. 2018 Jan 1;142(1):66-80 - PubMed
  2. Cell. 2014 Aug 14;158(4):929-944 - PubMed
  3. Lancet Oncol. 2015 Oct;16(13):1324-34 - PubMed
  4. Oncotarget. 2018 Nov 2;9(86):35623-35638 - PubMed
  5. Am J Cancer Res. 2017 Jan 01;7(1):98-114 - PubMed
  6. Genome Biol. 2015 Jul 14;16:140 - PubMed
  7. Nucleic Acids Res. 2010 Sep;38(16):e164 - PubMed
  8. J Cancer Res Clin Oncol. 2019 Mar;145(3):625-636 - PubMed
  9. Cancer Discov. 2015 Feb;5(2):118-23 - PubMed
  10. PLoS One. 2016 Sep 29;11(9):e0163138 - PubMed
  11. N Engl J Med. 2015 Jun 25;372(26):2509-20 - PubMed
  12. Sci Rep. 2019 Feb 7;9(1):1667 - PubMed
  13. Clin Cancer Res. 2018 Oct 15;24(20):5018-5027 - PubMed
  14. Clin Breast Cancer. 2017 Jun;17(3):e135-e142 - PubMed
  15. JCO Precis Oncol. 2017 Jul;2017: - PubMed
  16. N Engl J Med. 2018 Jan 11;378(2):113-125 - PubMed
  17. Clin Cancer Res. 2012 Nov 15;18(22):6373-83 - PubMed
  18. JCO Precis Oncol. 2017;2017:null - PubMed
  19. Nat Med. 2016 Jan;22(1):105-13 - PubMed
  20. BMC Genomics. 2015 Jul 07;16:503 - PubMed
  21. Sci Rep. 2018 Apr 16;8(1):6041 - PubMed
  22. Am J Cancer Res. 2018 Jan 01;8(1):2-15 - PubMed
  23. Sci Rep. 2016 Sep 16;6:33398 - PubMed
  24. Clin Breast Cancer. 2019 Apr;19(2):113-125.e4 - PubMed
  25. Oncogene. 2007 Apr 2;26(15):2157-65 - PubMed
  26. N Engl J Med. 2017 Aug 10;377(6):523-533 - PubMed
  27. Clin Cancer Res. 2014 Sep 15;20(18):4827-36 - PubMed
  28. Oncotarget. 2016 May 31;7(22):32731-53 - PubMed
  29. Clin Cancer Res. 2018 Dec 15;24(24):6556-6569 - PubMed
  30. Nature. 2013 Oct 17;502(7471):333-339 - PubMed
  31. PLoS One. 2015 Oct 09;10(10):e0140293 - PubMed
  32. J Pathol. 2018 Apr;244(5):610-615 - PubMed
  33. Am J Cancer Res. 2016 Nov 01;6(11):2611-2630 - PubMed
  34. Nature. 2000 Nov 16;408(6810):307-10 - PubMed
  35. Gynecol Oncol. 2019 Feb;152(2):375-386 - PubMed
  36. Br J Cancer. 2006 Sep 4;95(5):627-33 - PubMed
  37. Lancet Oncol. 2015 Dec;16(16):e579-80 - PubMed
  38. Breast Cancer Res. 2012 May 02;14(3):R70 - PubMed

Publication Types